Literature DB >> 9188573

Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.

H W Amtoft1, A B Sørensen, C Bareil, J Schmidt, A Luz, F S Pedersen.   

Abstract

Murine retrovirus SL3-3 is highly T lymphomagenic. Its pathogenic properties are determined by the transcriptional enhancer of the U3 repeat region which shows preferential activity in T cells. Within the U3 repeats, the major determinant of T-cell specificity has been mapped to binding sites for the AML1 transcription factor family (also known as the core binding factor [CBF], polyomavirus enhancer binding protein 2 [PEBP2], and SL3-3 enhancer factor 1 [SEF-1]). SL3-3 viruses with AML1 site mutations have lost a major determinant of T-cell-specific enhancer function but have been found to retain a lymphomagenic potential, although disease induction is slower than for the SL3-3 wild type. To compare the specificities and mechanisms of disease induction of wild-type and mutant viruses, we have examined lymphomas induced by mutant viruses harboring transversions of three consecutive base pairs critical to AML1 site function (B. Hallberg, J. Schmidt, A. Luz, F. S. Pedersen, and T. Grundström. J. Virol. 65:4177-4181, 1991). Our results show that the mutated AML1 sites are genetically stable during lymphomagenesis and that ecotropic provirus numbers in DNA of tumors induced by wild-type and mutant viruses fall within the same range. Moreover, proviruses were found to be integrated at the c-myc locus in similar proportions of wild-type and mutant SL3-3-induced tumors, and the mutated AML1 sites of proviruses at c-myc are unaltered. In some cases, however, including one c-myc-integrated provirus, a single-base pair change was detected in a second, weaker AML1 binding site. By DNA rearrangement analysis of the T-cell receptor beta-locus, tumors induced by the AML1 site mutants are found to be of the T-cell type. Thus, although the AML1 site mutants have weakened T-cell-specific enhancers they are T-lymphomagenic, and wild-type- and mutant-virus-induced tumor DNAs are similar with respect to the number of overall ecotropic and c-myc-integrated clonal proviruses. The SL3-3 wild-type and AML1 site mutant viruses may therefore induce disease by similar mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188573      PMCID: PMC191741          DOI: 10.1128/JVI.71.7.5080-5087.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences.

Authors:  C A Rosen; W A Haseltine; J Lenz; R Ruprecht; M W Cloyd
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

2.  Murine T lymphomas in which the cellular myc oncogene has been activated by retroviral insertion.

Authors:  L M Corcoran; J M Adams; A R Dunn; S Cory
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

3.  Proviruses are adjacent to c-myc in some murine leukemia virus-induced lymphomas.

Authors:  D Steffen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

4.  Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat.

Authors:  J Lenz; D Celander; R L Crowther; R Patarca; D W Perkins; W A Haseltine
Journal:  Nature       Date:  1984 Mar 29-Apr 4       Impact factor: 49.962

5.  A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.

Authors:  P A Chatis; C A Holland; J E Silver; T N Frederickson; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

6.  The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential.

Authors:  L DesGroseillers; P Jolicoeur
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

7.  Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.

Authors:  H L Morrison; B Soni; J Lenz
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  Oncogenic retrovirus from spontaneous murine osteomas. I. Isolation and biological characterization.

Authors:  J Schmidt; V Erfle; F S Pedersen; H Rohmer; H Schetters; K H Marquart; A Luz
Journal:  J Gen Virol       Date:  1984-12       Impact factor: 3.891

9.  5' flanking region of immunoglobulin heavy chain constant region genes displays length heterogeneity in germlines of inbred mouse strains.

Authors:  K B Marcu; J Banerji; N A Penncavage; R Lang; N Arnheim
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

10.  Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas.

Authors:  G Selten; H T Cuypers; A Berns
Journal:  EMBO J       Date:  1985-07       Impact factor: 11.598

View more
  13 in total

1.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.

Authors:  S Ethelberg; B D Tzschaschel; A Luz; S J Diaz-Cano; F S Pedersen; J Schmidt
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

3.  ALY is a common coactivator of RUNX1 and c-Myb on the type B leukemogenic virus enhancer.

Authors:  Jennifer A Mertz; Ryuji Kobayashi; Jaquelin P Dudley
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.

Authors:  S Ethelberg; J Lovmand; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  Sequence-specific and/or stereospecific constraints of the U3 enhancer elements of MCF 247-W are important for pathogenicity.

Authors:  N L DiFronzo; C A Holland
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

6.  Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.

Authors:  Anne Ahlmann Nielsen; Annette Balle Sørensen; Jörg Schmidt; Finn Skou Pedersen
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo.

Authors:  S Ethelberg; A B Sørensen; J Schmidt; A Luz; F S Pedersen
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  Core-binding factor influences the disease specificity of Moloney murine leukemia virus.

Authors:  A F Lewis; T Stacy; W R Green; L Taddesse-Heath; J W Hartley; N A Speck
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

9.  B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.

Authors:  J Lovmand; A B Sorensen; J Schmidt; M Ostergaard; A Luz; F S Pedersen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  A retroviral mutagenesis screen identifies Cd74 as a common insertion site in murine B-lymphomas and reveals the existence of a novel IFNgamma-inducible Cd74 isoform.

Authors:  Magdalena Pyrz; Bruce Wang; Matthias Wabl; Finn Skou Pedersen
Journal:  Mol Cancer       Date:  2010-04-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.